Abatacept in Juvenile Dermatomyositis
Abatacept in Juvenile Dermatomyositis
NCT ID: NCT02594735 Phase: PHASE4 Status: COMPLETED Enrollment: 10 Completion: 2021-10-22
Conditions
Dermatomyositis
Interventions
Abatacept
Summary
The purpose of this study is to assess the safety and efficacy of subcutaneous abatacept in 10 patients seven years of age and older with refractory JDM.
Primary Outcome
Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by ≥ 25% (Not Including the Manual Muscle Testing).